Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

AbbVie’s Cancer Expansion Is Paying Off

Jan 27 2017

• By Joseph Haas

Related Content

J.P. Morgan Notebook Day 3: Novartis' Cancer Reorg, AbbVie's Price Pledge, Genentech’s Partnering And More

Jan 12 2017

Keeping Track: Trulance Is First Novel Drug Of 2017; Vantrela ER Is Year's Second Abuse-Deterrent Opioid

Jan 22 2017

AbbVie Gains Lung Cancer ADC, Solid Tumor Platform With Stemcentrx Buyout

Apr 28 2016

Venclyxto Gets EU Nod – But Won't Be A Humira Replacement For AbbVie Yet

Oct 14 2016

Beyond Humira: How AbbVie Plans To Hold Its Immunology Leadership Reign

Jun 06 2016

AbbVie/J&J's Imbruvica On Track For New Indication In Graft-Versus-Host Disease

Dec 07 2016

Related Companies

AbbVie Inc.

Gilead Sciences, Inc.

Johnson & Johnson

Genentech, Inc.

Additional Topics

Sales & Earnings Business Strategies Commercial Cancer BioPharmaceutical

More from Earnings

More from Business

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window